Drug profile · INN
trimethoprim
ALPRIM
trimethoprim (ALPRIM) is a bacterial dihydrofolate reductase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — trimethoprim
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 7
- Data quality
- 0.89
Quick answer
trimethoprim (ALPRIM) is a bacterial dihydrofolate reductase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial dihydrofolate reductase inhibitor
Primary target: Dihydrofolate reductase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is trimethoprim?
trimethoprim (ALPRIM) is a bacterial dihydrofolate reductase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for trimethoprim?
ALPRIM is a marketed brand name for trimethoprim. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of trimethoprim?
trimethoprim has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.